HealthCor Management L.P. raised its stake in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 50.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 973,840 shares of the biopharmaceutical company’s stock after purchasing an additional 326,420 shares during the quarter. Clovis Oncology makes up about 2.2% of HealthCor Management L.P.’s holdings, making the stock its 23rd biggest holding. HealthCor Management L.P. owned about 1.99% of Clovis Oncology worth $66,221,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Gabelli Funds LLC increased its position in Clovis Oncology by 75.0% during the 3rd quarter. Gabelli Funds LLC now owns 15,400 shares of the biopharmaceutical company’s stock valued at $1,269,000 after purchasing an additional 6,600 shares during the period. Columbus Circle Investors increased its position in Clovis Oncology by 74.4% during the 3rd quarter. Columbus Circle Investors now owns 213,674 shares of the biopharmaceutical company’s stock valued at $17,607,000 after purchasing an additional 91,142 shares during the period. Prudential Financial Inc. increased its position in Clovis Oncology by 1,416.9% during the 3rd quarter. Prudential Financial Inc. now owns 66,560 shares of the biopharmaceutical company’s stock valued at $5,485,000 after purchasing an additional 62,172 shares during the period. Greenwood Capital Associates LLC increased its position in Clovis Oncology by 21.6% during the 4th quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 996 shares during the period. Finally, BB&T Securities LLC purchased a new position in Clovis Oncology during the 3rd quarter valued at $288,000.
A number of research analysts have issued reports on the stock. BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. Stifel Nicolaus reduced their price objective on shares of Clovis Oncology from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. SunTrust Banks reduced their price objective on shares of Clovis Oncology from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Cann reissued a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, February 27th. Finally, Barclays set a $85.00 price objective on shares of Clovis Oncology and gave the company a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $87.84.
Shares of Clovis Oncology Inc (NASDAQ:CLVS) opened at $62.12 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.35 and a current ratio of 7.69. Clovis Oncology Inc has a 1 year low of $45.42 and a 1 year high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.29) by $0.25. The firm had revenue of $17.04 million for the quarter, compared to the consensus estimate of $19.42 million. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The company’s revenue was up 21746.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.83) EPS. equities research analysts forecast that Clovis Oncology Inc will post -4.75 EPS for the current year.
WARNING: “Clovis Oncology Inc (CLVS) Shares Bought by HealthCor Management L.P.” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/12/clovis-oncology-inc-clvs-shares-bought-by-healthcor-management-l-p.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.